Drug Search Results
More Filters [+]

TAK-105

Alternative Names: tak-105, tak 105, tak105
Latest Update: 2023-06-22
Latest Update Note: Clinical Trial Update

Product Description

TAK-105 will be used to help treat people with nausea and vomiting

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TAK-105

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TAK-105-1001

P1

Completed

Healthy Volunteers

2023-06-19

28%

Recent News Events

Date

Type

Title